Dean G. Assimos

Dean G. Assimos

Auto-generated profile, based on publicly available information

Dean G. Assimos

Department of Urology, University of Alabama at Birmingham, Birmingham, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Urology
Verified
Journal Article
Closed access
JLJessica N. Lange
Jessica N. Lange
PMPatrick W. Mufarrij
Patrick W. Mufarrij
LELinda Easter
Linda Easter
JKJohn Knight
John Knight
RHRoss P. Holmes
Ross P. Holmes
DADean G. Assimos
Dean G. Assimos

1 January 2007 in AIP Conference Proceedings
Verified
Conference Paper
Closed access
RHRoss P. Holmes
Ross P. Holmes
JKJohn Knight
John Knight
DADean G. Assimos
Dean G. Assimos
Urinary oxalate is mostly derived from the absorption of ingested oxalate and endogenous synthesis. The breakdown of vitamin C may also contribute small amounts to the urinary oxalate pool. The amount of oxalate absorbed is influenced by the oxalate content of the diet, the concentrations of divalent cations in the gut, the presence of oxalate‐degrading organisms, transport characteristics of the intestinal epithelium, and other factors associated with the intestinal environment. Knowledge of pathways associated with endogenous oxalate synthesis is limited. Urinary oxalate excretion can be modified using strategies that limit dietary oxalate absorption and the ingestion of oxalogenic substrates such as hydroxyproline.

21 June 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CLCraig B. Langman
Craig B. Langman
DADean Assimos
Dean Assimos
MBMelanie Blank
Melanie Blank
JCJuan Calle
Juan Calle
AGAndreas Grauer
Andreas Grauer
OWon behalf of the Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup)
on behalf of the Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup)
Enteric hyperoxaluria is a medical condition characterized by elevated urinary oxalate excretion due to increased gastrointestinal oxalate absorption. Causative features include fat malabsorption and/or increased intestinal permeability to oxalate. Enteric hyperoxaluria has long been known to cause nephrolithiasis and nephrocalcinosis, and, more recently, an association with CKD and kidney failure has been shown. Currently, there are no US Food and Drug Administration–approved therapies for enteric hyperoxaluria, and it is unclear what end points should be used to evaluate the efficacy of new drugs and biologics for this condition. This study represents work of a multidisciplinary group convened by the Kidney Health Initiative to review the evidence supporting potential end points for clinical trials in enteric hyperoxaluria. A potential clinical outcome is symptomatic kidney stone events. Potential surrogate end points include (1) an irreversible loss of kidney function as a surrogate for progression to kidney failure, (2) asymptomatic kidney stone growth/new stone formation observed on imaging as a surrogate for symptomatic kidney stone events, (3) urinary oxalate and urinary calcium oxalate supersaturation as surrogates for the development of symptomatic kidney stone events, and (4) plasma oxalate as a surrogate for the development of the clinical manifestations of systemic oxalosis. Unfortunately, because of gaps in the data, this Kidney Health Initiative workgroup was unable to provide definitive recommendations. Work is underway to obtain robust information that can be used to inform trial design and medical product development in this space.



30 April 2026 in Journal of Urology
Verified
Journal Article
Closed access
DADean G. Assimos
Dean G. Assimos